Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. - Wikidata - wikimedia - TriplyDB

Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

http://www.wikidata.org/entity/Q34701929

about

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Dexamethasone intravitreal implant in the treatment of diabetic macular edema Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness.Hepcidin antagonists for potential treatments of disorders with hepcidin excess.Synthesis and evaluation of a nanoglobular dendrimer 5-aminosalicylic Acid conjugate with a hydrolyzable schiff base spacer for treating retinal degeneration.Planar microdevices enhance transport of large molecular weight molecules across retinal pigment epithelial cells.On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device.Ocular delivery of macromolecules Single compartment drug delivery.Bestrophin 1 and retinal disease.Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.Multifunctional PEG retinylamine conjugate provides prolonged protection against retinal degeneration in mice.Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids Microglial ramification and redistribution concomitant with the attenuation of choroidal neovascularization by neuroprotectin D1.Recent patents on ophthalmic nanoformulations and therapeutic implications Anatomic alterations in aging and age-related diseases of the eye.In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits.Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.Multivalent hyaluronic acid bioconjugates improve sFlt-1 activity in vitro.Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management.In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device.Ocular biocompatibility and structural integrity of micro- and nanostructured poly(caprolactone) films Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy.Drug and gene delivery to the back of the eye: from bench to bedside.Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers.Nanotechnology approaches for ocular drug delivery.Dendrimers for gene delivery--a potential approach for ocular therapy?Neurotrophin family members as neuroprotectants in retinal degenerations.A New Vision for the Eye: Unmet Ocular Drug Delivery Needs.Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery.Recent developments in ocular drug delivery.Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.A comprehensive insight on ocular pharmacokinetics.Thrombospondin-derived peptide attenuates Sjögren's syndrome-associated ocular surface inflammation in mice.Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy.A Brain-Derived Neurotrophic Factor Mimetic Is Sufficient to Restore Cone Photoreceptor Visual Function in an Inherited Blindness Model.Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats.Sustained protection against photoreceptor degeneration in tubby mice by intravitreal injection of nanoceria.Intravitreal infusion: A novel approach for intraocular drug delivery.

P2860

Q26771522-F103E956-7FF8-49B1-8432-5164BED7767C Q26799423-EA21EC95-BC2B-4851-8A1A-701F8C66FF3C Q30411312-7285A806-9DE1-4B26-AC47-4C800841FD11 Q33563777-243A824E-32F1-4445-BB65-F250CD040D32 Q33768680-DC4DD01D-6199-4D3F-B12F-C14D29D03A3F Q33849404-99ED331B-98E4-4A37-95DE-4C1F49093C66 Q33941341-73FB0EF0-70C5-4B89-833A-441FAD04E35E Q34079676-4D9E2564-CD97-4748-8FB9-6738FD9F4BB4 Q34263907-F3C7B41F-F2A6-4F16-91CD-C5DA0650E153 Q34550522-3352B22C-779E-4ADE-8CD2-7510C12B57D0 Q34603733-B7218EA7-DA63-49C6-AE30-C6D06CAFEAA4 Q34669685-6500F858-49A9-4116-9126-00ECDC342890 Q34856993-5EB3D2E9-27B6-480D-B4B9-B45D4E6552D9 Q34901419-1DF545A5-AE14-41AB-A943-02A7F52E30F2 Q35043004-05AEF7B6-0C49-4D0E-88E0-05F1D01C3419 Q35066318-16D4CA01-D5EA-4D02-BCC4-CD8C5E5A40F0 Q35518911-ABE4A2CE-A25E-4814-BAB8-781054B81FD8 Q35759073-58AFE849-D274-47DF-A576-BDE3F9D2BD66 Q35991894-DA0B5FDF-DC69-4006-8F0D-20ECC58A3A71 Q36013578-1D2BB312-9A7C-4092-9321-E0E52EA03EBF Q36273801-6E7C161B-1685-42B6-B25C-3205ACF3915D Q36696921-3CA0B273-B02B-4B04-A553-4AFB32554518 Q37088862-05E39D6F-A3BD-40FA-A962-EC881FFB4950 Q37731899-824C5C3E-11A4-4258-8748-51D28978E701 Q38017713-C5F756E8-EEE8-4C9D-AF99-B009D59B9F34 Q38098509-EA5630BB-6FE7-4E59-B4C4-1B523B13B8F6 Q38196447-2FBB4967-022E-4AB2-9919-EB63A3BD427C Q38269424-0607874B-0DFC-4CA6-8570-DE46E1536DF3 Q38521315-FB78C5CB-0267-41B5-8E22-31D44747DB3D Q38573732-6706402C-7FB1-470D-9A4C-31FABC2D7527 Q38603354-18E91E3E-5723-4BEB-BBCC-CDC90A6359FD Q38829320-107FBB2E-4B43-437B-98DA-A24762CA0D38 Q38995367-43D818A6-7A32-488D-BBE7-C274A164CFFD Q39052707-824B72C8-0FFC-4747-A642-81877496B7B8 Q39087808-CB9B6A80-290E-4471-8601-94E354959764 Q39103248-AC4F11F7-A786-4E78-BE30-1E0B96D127FA Q41195219-27318794-0DF0-46C6-A816-8AFDD5A3B6EE Q41597703-7FE9B1E6-1D5D-432D-A901-688863919B93 Q42019986-C5230EB6-EFA9-4651-9B8C-22229C72CDF0 Q42183376-816244BA-3427-485A-88F5-6F1965712DD2

P2860

Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

http://www.wikidata.org/entity/Q34701929

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Ophthalmic drug delivery syste ...... arch to clinical applications.

@ast

Ophthalmic drug delivery syste ...... arch to clinical applications.

@en

Ophthalmic drug delivery syste ...... arch to clinical applications.

@nl

type

label

Ophthalmic drug delivery syste ...... arch to clinical applications.

@ast

Ophthalmic drug delivery syste ...... arch to clinical applications.

@en

Ophthalmic drug delivery syste ...... arch to clinical applications.

@nl

prefLabel

Ophthalmic drug delivery syste ...... arch to clinical applications.

@ast

Ophthalmic drug delivery syste ...... arch to clinical applications.

@en

Ophthalmic drug delivery syste ...... arch to clinical applications.

@nl

P1433

Q34701929-BBC243E3-D7CE-4040-834E-980D84E6F0A5

P1476

Q34701929-3045F6DF-EA9F-41F4-A41C-FF8B3666B2B8

P2093

Q34701929-13603F99-92D6-47B1-9342-AE1DE637F5D7

Q34701929-28C96413-61FE-4647-8B29-D8D087F03FF5

Q34701929-29D75315-4E60-4FBB-852D-6F9F705ECEEA

Q34701929-2FEB01FE-6872-49A6-B953-E186B73BADD8

Q34701929-336176DA-4829-40F9-B6AE-4C459C57D36A

Q34701929-74725A8E-1F4F-47FA-A5C4-13379185813A

Q34701929-77E24241-8C78-4F6E-A75E-D2DFAB10C11A

Q34701929-99AF455C-A529-41B3-BFB7-4B16EA7DD868

Q34701929-9D9BE6E5-E8F7-402F-AD0E-90124059821D

Q34701929-B1D2E511-90A8-49FE-8A3C-A532731348E4

P2860

Q34701929-06B91DCD-BBCF-4CBC-B762-830A628B3F21

Q34701929-0864087E-991E-418F-8B52-88497813FAA3

Q34701929-0B3BEA67-D700-49AF-8DD2-0A9D95E41D47

Q34701929-1FD9167D-010D-4836-AEB0-EECDE8B714AE

Q34701929-20E06F58-2131-4ECE-8BD8-D93244344C13

Q34701929-217A15FE-2365-4023-9204-F925F906D2F6

Q34701929-219CFA3B-83C7-4423-B49C-915D8BB2D1F8

Q34701929-24B5A897-D72B-479D-91D9-A14D09872285

Q34701929-276298B1-2041-4A0C-936B-B57782CFFC22

Q34701929-277D2291-76BF-429C-AD2B-9C046FA00E85

P304

Q34701929-A651C0AD-AE41-43C5-BDF0-D92F9204BC32

P31

Q34701929-FB5E80BB-D1E4-41F2-8851-26805112F36C

P356

Q34701929-3B721DAB-8665-43BF-9294-24CE5AC40598

P407

Q34701929-1FE8A393-18CC-4BCF-9483-143297C8C68C

P433

Q34701929-5870D008-2776-433B-A814-A0558D15D9CA

P478

Q34701929-6F1ADF04-87C2-4A53-9AF6-193C7585840C

P50

Q34701929-ED4ABE9F-40B8-496B-B9FC-144C640F4679

P577

Q34701929-0D8E6D6D-3953-4689-BA17-ED4A2666D7E0

P5875

Q34701929-F4DB9AAA-F1E6-492E-88D0-73758AE0AE2F

P698

Q34701929-4E4529BB-8F8F-430C-B232-BB97199D7262

P921

Q34701929-57AC2727-21D6-4177-A591-E32CEFC84F07

P932

Q34701929-DF1D8B3C-0944-4CED-AC57-550ED638B9E4

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

Ophthalmic drug delivery syste ...... arch to clinical applications.

@en

P2093

Baruch D Kuppermann

http://www.w3.org/2001/XMLSchema#string

Brian C Gilger

http://www.w3.org/2001/XMLSchema#string

Cheryl L Rowe-Rendleman

http://www.w3.org/2001/XMLSchema#string

Clive G Wilson

http://www.w3.org/2001/XMLSchema#string

Daniel G Dawson

http://www.w3.org/2001/XMLSchema#string

David A Weber

http://www.w3.org/2001/XMLSchema#string

Gerald J Chader

http://www.w3.org/2001/XMLSchema#string

Gregory S Hageman

http://www.w3.org/2001/XMLSchema#string

Hans E Grossniklaus

http://www.w3.org/2001/XMLSchema#string

Henry F Edelhauser

http://www.w3.org/2001/XMLSchema#string

P2860

Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study.

Topical nepafenac inhibits ocular neovascularization.

Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment.

Binding of betaxolol, metoprolol and oligonucleotides to synthetic and bovine ocular melanin, and prediction of drug binding to melanin in human choroid-retinal pigment epithelium.

Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.

The spectrum of complement alternative pathway-mediated diseases.

SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion

A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration

Novel drug delivery systems for retinal diseases. A review.

P304

5403-5420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.10-5392

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Scott M Whitcup

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47566691

http://www.w3.org/2001/XMLSchema#string

P698

20980702

http://www.w3.org/2001/XMLSchema#string

P921

P932

3061492

http://www.w3.org/2001/XMLSchema#string